UBS Group’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-66,225
| Closed | -$2.24M | – | 11048 |
|
|
2025
Q4 | $2.24M | Buy |
66,225
+37,417
| +130% | +$1.16M | ﹤0.01% | 4867 |
|
|
2025
Q3 | $743K | Buy |
28,808
+25,116
| +680% | +$329K | ﹤0.01% | 5803 |
|
|
2025
Q2 | $29.5K | Sell |
3,692
-16,413
| -82% | -$125K | ﹤0.01% | 8170 |
|
|
2025
Q1 | $196K | Buy |
20,105
+1,396
| +7% | +$13.7K | ﹤0.01% | 6575 |
|
|
2024
Q4 | $236K | Buy |
18,709
+15,103
| +419% | +$192K | ﹤0.01% | 6352 |
|
|
2024
Q3 | $58K | Buy |
3,606
+32
| +0.9% | +$647 | ﹤0.01% | 6722 |
|
|
2024
Q2 | $87.2K | Sell |
3,574
-3,372
| -49% | -$156K | ﹤0.01% | 6278 |
|
|
2024
Q1 | $499K | Sell |
6,946
-4,305
| -38% | -$599K | ﹤0.01% | 5207 |
|
|
2023
Q4 | $2.24M | Buy |
11,251
+6,963
| +162% | +$862K | ﹤0.01% | 3695 |
|
|
2023
Q3 | $570K | Sell |
4,288
-1,637
| -28% | -$267K | ﹤0.01% | 4560 |
|
|
2023
Q2 | $886K | Sell |
5,925
-176
| -3% | -$27.4K | ﹤0.01% | 4352 |
|
|
2023
Q1 | $896K | Sell |
6,101
-6,367
| -51% | -$1.29M | ﹤0.01% | 4216 |
|
|
2022
Q4 | $1.97M | Buy |
12,468
+11,029
| +766% | +$1.77M | ﹤0.01% | 3401 |
|
|
2022
Q3 | $277K | Buy |
1,439
+1,103
| +328% | +$209K | ﹤0.01% | 4831 |
|
|
2022
Q2 | $49K | Sell |
336
-5,284
| -94% | -$704K | ﹤0.01% | 5932 |
|
|
2022
Q1 | $989K | Sell |
5,620
-4,144
| -42% | -$783K | ﹤0.01% | 4109 |
|
|
2021
Q4 | $2.87M | Buy |
9,764
+8,985
| +1,153% | +$2.4M | ﹤0.01% | 3407 |
|
|
2021
Q3 | $193K | Buy |
779
+7
| +0.9% | +$1.85K | ﹤0.01% | 5349 |
|
|
2021
Q2 | $196K | Sell |
772
-350
| -31% | -$65.4K | ﹤0.01% | 5364 |
|
|
2021
Q1 | $199K | Buy |
1,122
+109
| +11% | +$18K | ﹤0.01% | 5491 |
|
|
2020
Q4 | $160K | Sell |
1,013
-1,414
| -58% | -$307K | ﹤0.01% | 5378 |
|
|
2020
Q3 | $626K | Buy |
2,427
+481
| +25% | +$107K | ﹤0.01% | 3997 |
|
|
2020
Q2 | $451K | Buy |
1,946
+1,747
| +878% | +$270K | ﹤0.01% | 4234 |
|
|
2020
Q1 | $34K | Sell |
199
-168
| -46% | -$38.3K | ﹤0.01% | 6124 |
|
|
2019
Q4 | $81K | Buy |
+367
| New | +$67.6K | ﹤0.01% | 6103 |
|
UBS Group's RAPT Position: Q1 2026 in Review
UBS Group sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 66,225 shares — an estimated $2.24M sold.
UBS Group first reported a position in RAPT in Q4 2019 and held it in 25 quarters. The position peaked at $2.87M in Q4 2021. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- UBS Group reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- UBS Group sold 66,225 RAPT Therapeutics shares in Q1 2026, an estimated $2.24M.
- UBS Group first reported a position in RAPT Therapeutics in Q4 2019 and held it in 25 quarters.
- UBS Group's RAPT Therapeutics position peaked at $2.87M in Q4 2021.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.